Disease Control Technologies (DCT) and Clariant donate Royal Sentry® Long Lasting Insecticide Treated Mosquito Nets (LLINs) to charities in Nicaragua on occasion of World Malaria Day 2015


Disease Control Technologies (DCT) and Clariant donate Royal Sentry® Long Lasting Insecticide Treated Mosquito Nets (LLINs) to charities in Nicaragua on occasion of World Malaria Day 2015

·  Following a WHO initiated call to step up the fight against diseases spread by insects, DCT and Clariant have partnered to donate 600 state-of-the-art mosquito nets and curtains to charitable institutions in Nicaragua.

· High quality Royal Sentry® brand Long Lasting Insecticide Treated Nets (LLINs) produced by DCT are equipped with Clariant’s unique slow release technology to prevent malaria transmission and other harmful diseases spread by insects.

Greenville, SC, April 24, 2015 – U.S based Disease Control Technologies (DCT) and its supplier partner Clariant, a world leader in specialty chemicals, donated 600 Long Lasting Insecticide Treated Mosquito Nets (LLINs) and curtains in an effort to combat the spread of Malaria, Dengue, and Chikengunya to four charities in Managua, Nicaragua including Damain Foundation, Conanca Charity, Masaya Hospital, and Asociación Hoy Por Manana. The donations were passed to representatives of the charitable institutions on the occasion of World Malaria Day 2015. With this event the WHO and the global malaria control community highlight the annual death toll of approximately half a million lives that malaria still claims each year.

One of the principal control measures against mosquito transmitted diseases is the usage of World Health Organization (WHO) approved LLINs. The mosquito nets produced by DCT, are one of only a handful of LLIN products fully approved by the WHO, which comply with the strict standards for durability and washability set by the World Health Organization Pesticide Evaluation Scheme (WHOPES). Royal Sentry® brand LLINs are manufactured  from a special additive masterbatch supplied to DCT by Clariant’s Masterbatch Business Unit; the masterbatch contains a pyrethroid insecticide  that is highly effective against insects and safe for for human use. The treated fabric maintains its biological effectiveness for several years, and over 20 home wash cycles.

“Our partnership with DCT has been a brilliant success story in regards to combating the spread of diseases, such as Malaria and Dengue. We are proud to provide the vital and basic components for DCT to create its LLINs and happy to see them in use here in Managua and everywhere people are affected”, comments Francis Baud, Clariant’s BU representative in the field.

Andy Butenhoff, DCT’s Managing Director, states that “DCT is proud to partner with Clariant as a part of a global community striving to eradicate malaria deaths worldwide.  We are hopeful our contributions, both for World Malaria Day 2015 and every day, make a difference to people in countries burdened with malaria and other vector borne diseases.”

One recipient of the donation, Asociación Hoy Por Manana, operates the shelter Hogar San Jose Protector for 70 young girls ages three to eighteen from impoverished families. Ena Flinn, who is representing the board of directors of the charity expressed her gratitude for this “anti-mosquito”effort by Clariant and DCT. “The donation in the spirit of World Malaria Day will help protect the children and their families in their dwellings from contracting such illnesses.”



Shifting Development Priorities Must not Slow Malaria Fight

In Advance of World Malaria Day, the Roll Back Malaria Partnership Urges Increased Investment for Global Malaria Elimination 

(21 April 2015; Geneva/New York) As communities worldwide prepare to commemorate the last World Malaria Day under the United Nations Millennium Development Goals (MDGs) this 25th of April, the Roll Back Malaria (RBM) Partnership highlights that progress made against malaria – while remarkable – remains fragile. With just months before the MDGs expire at the end of 2015 and the world transitions to an ambitious set of Sustainable Development Goals (SDGs) to guide efforts through 2030, RBM partners across sectors have taken this opportunity to mark the progress made while urging the importance of sustained commitment to build on the successes achieved since the turn of the millennium. 

 “Malaria control has proven to be one of the smartest investments in health we can make. This is why it is one of my priorities,” the United Nations Secretary-General Ban Ki-moon said. “When we target our funds in proven malaria control interventions, we create healthier communities and more robust economies. Now more than ever, partnership will be crucial to ensure we can build on our successes and leave no one behind.”  

According to the latest report by the World Health Organization (WHO), malaria mortality rates have decreased by 47% worldwide since 2000 and 54% in Africa alone – which accounts for some 80% of global malaria cases – during the same time. Since 2001, it is estimated that more than 4 million malaria-related deaths have been averted, approximately 97% of which have been children under 5. 

As a result of stronger coordination among RBM partners, with  technical guidance by the World Health Organization and increased financing, 64 of 97 countries are on track to meet the malaria-specific MDG target to begin reversing malaria incidence by 2015, of which 55 are also aiming to reduce malaria case incidence by 75%. Today, fewer people than ever before in Africa are getting infected with malaria, and many countries around the world are focusing on elimination targets for the first time in history, with new regional commitments to malaria elimination announced in Mesoamerica, the Asia-Pacific and Africa. 

Despite unprecedented progress, malaria caused an estimated 198 million cases of infection globally in 2013, claiming the lives of approximately 584,000 – nearly 80% of which were children under 5. This preventable and treatable disease continues to kill one child every minute for lack of a simple, cost-effective tools like an insecticide-treated net or a simple course of effective treatment. 

“We have come half the distance with half the funds,” said Dr. Fatoumata Nafo-Traoré, Executive Director of the Roll Back Malaria Partnership. “To beat growing threats like insecticide and drug resistance, we must re-commit ourselves and raise our ambitions. We must continue to tackle the unfinished business of the MDGs and aim for elimination in the next 15 years.” 

With more than half of the world’s population at risk of infection, malaria presents an alarming threat to global development. Each year, malaria costs the African continent an estimated minimum of US $12 billion in lost productivity, and in some high-burden countries it can account for as much as 40% of public health expenditure.  

Malaria control interventions help advance broader development efforts by reducing school absenteeism, fighting poverty, increasing gender parity and improving maternal and child health. Lives saved from malaria control interventions have been linked to a 20% reduction in all-cause child mortality in sub-Saharan Africa since 2000 and have helped drive progress against MDG4, while efforts to prevent malaria in pregnancy have averted nearly 95,000 newborn deaths between 2009 and 2012. These numbers represent an entire generation given the chance to live healthy lives and grow into strong, contributing members of their societies. 

Still, efforts continue to leave communities behind. In Africa alone, 10,000 women and as many as 200,000 infants are estimated to die annually as a result of malaria infection during pregnancy. In 2013, an estimated 15 million of the 35 million pregnant women in sub-Saharan Africa did not receive a single dose of preventive treatment during their pregnancy to protect them and their unborn child from malaria. In response, the RBM Partnership has issued a global call to action to increase national coverage with preventive treatment in pregnancy. 

Adequate and predictable financing and innovations for new tools will be critical to scale-up interventions and continue progress toward ambitious malaria elimination targets. While total international and domestic financing peaked at US $2.6 billion in 2013, this remains significantly lower than the US $5.1 billion RBM estimates is needed annually to achieve universal access and meet global targets.  

Experts estimate that just more than US $100 billion is needed to completely eliminate malaria by 2030. A high price tag, this investment carries a significant return: a potential 12 million lives saved, nearly 3 billion cases averted worldwide and a global gain of US $270 billion if the disease is eliminated in sub-Saharan Africa alone. 

Later this year, the RBM Partnership will launch its second generation global malaria action plan – Action and Investment to defeat Malaria (AIM) 2016-2030: for a Malaria-Free World – which, together with the WHO’s updated Global Technical Strategy: 2016-2030, makes the case for eliminating the scourge of malaria over the next 15 years and avoiding the resurgence of the disease, with its associated crippling economic cost and avoidable deaths.  

“Over the past fifteen years, we have seen that we have the tools necessary to overcome malaria and unlock potential in communities around the world,” said Dr. Pedro Alonso, Director of the World Health Organization’s Global Malaria Programme. “Now, more than ever, we must continue working together in partnership and making bold investments in malaria so that we can deliver on the promises we’ve made to the people of the world.” 

Instituted by WHO Member States during the 2007 World Health Assembly, World Malaria Day is celebrated on 25 April each year to highlight the need for continued investment and sustained political commitment for malaria control and elimination. The theme for the 2013-2015 campaign is “Invest in the Future. Defeat malaria”.

Media Contact

Mr. Trey Watkins (EN, SP)

RBM External Relations Officer

+1 646 626 6054 (office); +1 347 931 0667 (mobile)



Mr. Hervé Verhoosel (FR, EN)

RBM Head of External Relations

+1 917 345 5238 (mobile); hverhoosel@rbmny.org


Mr. Michel Aublanc (FR)

Consultant, RBM (Paris)
+33 6 08 719 795; michel.aublanc@orange.fr

Ms. Pru Smith (EN)

RBM Communications Advisor

+41 22 79 14586; smithp@who.int

 The Roll Back Malaria Partnership (RBM)

RBM is the global framework for coordinated action against malaria. Founded in 1998 by UNICEF, WHO, UNDP and the World Bank and strengthened by the expertise, resources and commitment of more than 500 partner organizations, RBM is a public-private partnership that facilitates the incubation of new ideas, lends support to innovative approaches, promotes high-level political commitment and keeps malaria high on the global agenda by enabling, harmonizing and amplifying partner-driven advocacy initiatives. RBM secures policy guidance and financial and technical support for control efforts in countries and monitors progress towards universal goals.


World Malaria Day 2015


World Malaria Day 2015

Disease Control Technologies is committed to globally helping people. By providing effective and innovative products that fight vector-borne diseases such as malaria, we help save lives. 

Raising awareness of malaria as a preventable and treatable disease is critical.  World Malaria Day was established and approved at the 60th World Health Assembly (WHA) in March 2007. It replaced Africa Malaria Day which was commemorated every year since 2001 on 25 April. On World Malaria Day advocates and citizens around the world raise awareness of malaria as a disease that is preventable and treatable and mobilize action to end the ravages of malaria.

The following are key facts provided by www.worldmalariaday.org.  Won't you help spread the word?

Cases, 2013

  •  Globally: 198 million

Deaths, 2013

  • Globally: 584 000
  • 90% of all malaria deaths occur in sub-Saharan Africa
  • and 78% occur in children under five

Population at risk

  • 3.2 billion (half of the world population), of whom 1.2 billion are at high risk

Affected countries

  • In 2014, 97 countries had on-going malaria transmission.
  • 80% of estimated malaria deaths occur in 18 most affected countries.
  • About 40% of malaria deaths occur in just two countries: Nigeria and the Democratic Republic of the Congo


  • The malaria mortality rate was reduced in 2000 – 2013
  • Globally: by 47%
  • in WHO African Region: by 54 %
  • 55 countries are on track to reduce their malaria case incidence rates by 75%, in line with World Health Assembly and Roll Back Malaria targets for 2015.
  • These 55 countries only account for 4% (8 million) of the total estimated malaria cases.
  • 64 countries are on track to meet the Millennium Development Goal target of reversing the incidence of malaria (between 2000 and 2015).


  • Between 2001 and 2013, an estimated 4.2 million lives were saved as a result of a scale-up of malaria interventions.
  • 97%, or 4.1 million, of these lives saved are in the under-five age group, in sub-Saharan Africa.

Required health expenditure

  • US$ 5.1 billion is needed every year
  • In 2013, the global total of international and domestic funding for malaria was US$ 2.6 billion – less than half of what is needed.

Economic cost

  • Direct: USD 12 billion per year in direct losses,
  • lost 1.3% of GDP growth per year for Africa


DCT joins Gates Foundation Innovation to Impact Stakeholder Convening


DCT joins Gates Foundation Innovation to Impact Stakeholder Convening

Managing Director of Disease Control Technologies, Andy Butenhoff, recently attended the Bill and Melinda Gates Foundation Innovation to Impact (I2I) Stakeholder Convening in Seattle, Washington.  It was an impactful meeting confirming the commitment of all involved to eradicate malaria through vector control.

Gates Foundation has recently committed $500 million to tackle the burden of infections disease in developing countries.  “We must remain committed to the eradication of malaria,” Gates said. “Small steps won’t get the job done. History shows that the only way to stop malaria is to end it forever.”  He emphasized, however, that long-range efforts to achieve eradication must not distract donors and endemic countries from the immediate objective of “saving lives now.”

DCT is committed to saving lives and stamping out malaria.  "We are excited to be a stakeholder in this Gates Foundation initiative," says Butenhoff.  "Over coming months, we will work hand and hand with others to shift from alignment to action in multiple I2I touchpoint areas."

Learn more about the Gates Foundation malaria strategy, Accelerate to zero, at http://www.gatesfoundation.org/What-We-Do/Global-Health/Malaria.



Scale-up in effective malaria control dramatically reduces deaths


Scale-up in effective malaria control dramatically reduces deaths

News release

9 DECEMBER 2014 ¦ GENEVA - The number of people dying from malaria has fallen dramatically since 2000 and malaria cases are also steadily declining, according to the World malaria report 2014. Between 2000 and 2013, the malaria mortality rate decreased by 47% worldwide and by 54% in the WHO African Region - where about 90% of malaria deaths occur.

New analysis across sub-Saharan Africa reveals that despite a 43% population increase, fewer people are infected or carry asymptomatic malaria infections every year: the number of people infected fell from 173 million in 2000 to 128 million in 2013.

“We can win the fight against malaria,” says Dr Margaret Chan, Director-General, WHO. “We have the right tools and our defences are working. But we still need to get those tools to a lot more people if we are to make these gains sustainable.”

“We have the right tools and our defences are working. But we still need to get those tools to a lot more people if we are to make these gains sustainable.”

Dr Margaret Chan, WHO Director-General.

Between 2000 and 2013, access to insecticide-treated bed nets increased substantially. In 2013, almost half of all people at risk of malaria in sub-Saharan Africa had access to an insecticide-treated net, a marked increase from just 3% in 2004. And this trend is set to continue, with a record 214 million bed nets scheduled for delivery to endemic countries in Africa by year-end.

Access to accurate malaria diagnostic testing and effective treatment has significantly improved worldwide. In 2013, the number of rapid diagnostic tests (RDTs) procured globally increased to 319 million, up from 46 million in 2008. Meanwhile, in 2013, 392 million courses of artemisinin-based combination therapies (ACTs), a key intervention to treat malaria, were procured, up from 11 million in 2005.

Moving towards elimination

Globally, an increasing number of countries are moving towards malaria elimination, and many regional groups are setting ambitious elimination targets, the most recent being a declaration at the East Asia Summit to eliminate malaria from the Asia-Pacific region by 2030.

In 2013, 2 countries reported zero indigenous cases for the first time (Azerbaijan and Sri Lanka), and 11 countries succeeded in maintaining zero cases (Argentina, Armenia, Egypt, Georgia, Iraq, Kyrgyzstan, Morocco, Oman, Paraguay, Uzbekistan and Turkmenistan). Another 4 countries reported fewer than 10 local cases annually (Algeria, Cabo Verde, Costa Rica and El Salvador).

Fragile gains

But significant challenges remain: “The next few years are going to be critical to show that we can maintain momentum and build on the gains,” notes Dr Pedro L Alonso, Director of WHO’s Global Malaria Programme.

In 2013, one third of households in areas with malaria transmission in sub-Saharan Africa did not have a single insecticide treated net. Indoor residual spraying, another key vector control intervention, has decreased in recent years, and insecticide resistance has been reported in 49 countries around the world.

Even though diagnostic testing and treatment have been strengthened, millions of people continue to lack access to these interventions. Progress has also been slow in scaling up preventive therapies for pregnant women, and in adopting recommended preventive therapies for children under 5 years of age and infants.

In addition, resistance to artemisinin has been detected in 5 countries of the Greater Mekong subregion and insufficient data on malaria transmission continues to hamper efforts to reduce the disease burden.

Dr Alonso believes, however, that with sufficient funding and commitment huge strides forward can still be made. “There are biological and technical challenges, but we are working with partners to be proactive in developing the right responses to these. There is a strong pipeline of innovative new products that will soon transform malaria control and elimination. We can go a lot further,” he says.

While funding to combat malaria has increased threefold since 2005, it is still only around half of the US$ 5.1 billion that is needed if global targets are to be achieved.

“Against a backdrop of continued insufficient funding the fight against malaria needs a renewed focus to ensure maximum value for money,” says Fatoumata Nafo-Traoré, Executive Director of the Roll Back Malaria Partnership. “We must work together to strengthen country ownership, empower communities, increase efficiencies, and engage multiple sectors outside health. We need to explore ways to do things better at all levels.”

Ray Chambers, who has served as the UN Secretary-General’s Special Envoy for Malaria since 2007, highlights the remarkable progress made in recent years. “While staying focused on the work ahead, we should note that the number of children dying from malaria today is markedly less than 8 years ago. The world can expect even greater reductions in malaria cases and mortality by the end of 2015, but any death from malaria remains simply unacceptable,” he says.

Gains at risk in Ebola-affected countries

At particular risk is progress on malaria in countries affected by the Ebola virus. The outbreak in West Africa has had a devastating impact on malaria treatment and the roll-out of malaria interventions. In Guinea, Sierra Leone and Liberia, the 3 countries most severely affected by the epidemic, the majority of inpatient health facilities remain closed, while attendance at outpatient facilities is down to a small fraction of rates seen prior to the outbreak.

Given the intense malaria transmission in these 3 countries, which together saw an estimated 6.6 million malaria cases and 20 000 malaria deaths in 2013, WHO has issued new guidance on temporary measures to control the disease during the Ebola outbreak: to provide ACTs to all fever patients, even when they have not been tested for malaria, and to carry out mass anti-malaria drug administration with ACTs in areas that are heavily affected by the Ebola virus and where malaria transmission is high. In addition, international donor financing is being stepped up to meet the further recommendation that bednets be distributed to all affected areas.

Note to editors

Globally, 3.2 billion people in 97 countries and territories are at risk of being infected with malaria. In 2013, there were an estimated 198 million malaria cases worldwide (range 124-283 million), 82% of which were in the WHO African region. Malaria was responsible for an estimated 584 000 deaths worldwide in 2013 (range: 367 000 – 755 000), killing an estimated 453 000 children under five years of age.

Based on an assessment of trends in reported malaria cases, a total of 64 countries are on track to meet the Millennium Development Goal target of reversing the incidence of malaria. Of these, 55 are on track to meet Roll Back Malaria and World Health Assembly targets of reducing malaria case incidence rates by 75% by 2015.

The World malaria report 2014 will be launched on 9 December 2014 in the United Kingdom Houses of Parliament. The event will be co-hosted by the All-Party Parliamentary Group on Malaria and Neglected Tropical Diseases (APPMG) and Malaria No More UK.

For more information:

Christian Lindmeier
WHO Media
Mobile: +41 7 95 00 65 52 
Telephone: +41 22 791 1948 
Email: lindmeierch@who.int

Alison Clements-Hunt
WHO Communications Officer
Telephone: +41 22 791 1995
Email: clementshuntal@who.int


Disease Control Technologies Donates 500 Nets to HBO for Movie


Disease Control Technologies Donates 500 Nets to HBO for Movie

Disease Control Technologies donated 500 nets to HBO for the production of Mary and Martha, starring oscar winner Hilary Swank and oscar nominee, Brenda Blethyn. The film was written by Richard Curtis whom has been involved with the fight against malaria through the United Kingdom's Comic Relief effort to raise funds and awareness for charitable causes.  The character, Martha, was inspired by a real mother who lost her child to malaria after volunteering in Ghana.

As reported by USA Today, Curtis says, "I consider it a good thing to get more information and familiarity about malaria out there, so that if the government says we're going to give some money to this thing, it rings a bell with people."  

DCT is proud to be a part of a film that both engages the emotions of viewers as well as informs with the hopes that these two components will encourage support that will save lives. 

Furthering the impact of the film, Malaria No More donated 50,000 malaria treatments to children in Africa with 50,000 views of theMary and Martha trailer on World Malaria Day.

Watch the trailer below